6:33 PM
 | 
Dec 07, 2015
 |  BC Extra  |  Clinical News

Alnylam reports hemophilia, PNH interim data

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $11.24 (10%) to $97.72 on Monday after it reported interim data from a Phase I study of fitusiran ( ALN-AT3) to treat hemophilia A and B and a Phase I/II dose-ranging study of ALN-CC5 to treat paroxysmal nocturnal hemoglobinuria.

Alnylam said the most effective weekly dose of fitusiran, 45 ug/kg, reduced antithrombin levels by a mean maximum of 55%...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >